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Australia, Perth, Western Australia, AustraliaIntroduction: The impact of time to treatment on clinical outcome is an established precept in infectious
disease but is not established in peritoneal dialysis–related peritonitis (PDRP).
Methods: In a prospective multicenter study of PDRP, symptom-to-contact time (SC), contact-to-treatment
time (CT), deﬁned as the time from health care presentation to initial antibiotic, and symptom-to-treatment
time (ST) were determined.
Results: One hundred sixteen patients had 159 episodes of PDRP. Median SC for all episodes was 5.0
hours (ﬁrst to third quartile [Q1–Q3]: 1.3–13.9); CT, 2.3 hours (Q1–Q3: 1.2–4.0); and ST, 9.0 hours (Q1–Q3:
4.7–25.3). Thirty-eight (23.9%) patient episodes (28 catheter removals and 10 deaths) met the primary
composite outcome of PD failure at 30 days (PD-fail). The risk of PD-fail increased by 5.5% for each hour of
delay of administration of antibiotics (odds ratio [OR] for CT: 1.055; 95% conﬁdence interval [CI]: 1.005–
1.109; P ¼ 0.032). Neither SC (OR: 1.00; 95% CI: 0.99–1.01; P ¼ 0.74) nor ST (OR: 1.00; 95% CI: 0.99–1.01; P ¼
0.48) was associated with PD-fail. In a multivariable analysis, only CT for presentation to a hospital-based
facility compared with a community facility (OR: 1.068; 95% CI: 1.013–1.126; P ¼ 0.015) and female sex
(OR: 2.4; 95% CI: 1.1–5.4; P ¼ 0.027) were independently associated with PD-fail. Each hour of delay in
administering antibacterial therapy from the time of presentation to a hospital facility increased the risk of
PD failure or death by 6.8%.
Discussion: Strategies targeted to expedited antibiotic treatment should be implemented to improve
outcomes from PDRP.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n Australia peritoneal dialysis (PD) is the initialchoice of renal replacement therapy for 19% of all
dialysis patients; however, only 8% of patients remain
on PD for more than 5 years, principally due to tech-
nique failure associated with peritonitis.1,2 Observa-
tional studies have variably identiﬁed multiple risk
factors for PD peritonitis, including residual renal
function, female sex, indigenous or ethnic origin, lower
socioeconomic status, older age, continuous ambulatory
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International Reports (2016) 1, 65–72coronary artery disease, chronic lung disease, and hy-
pertension.3,4 Prior episodes of peritonitis,5 exit-site
infection,6,7 nasal carriage of Staphylococcus aureus,8
and organism virulence9 have also been implicated,
and recent peritonitis or antimicrobial therapy has been
shown to increase the risk of fungal peritonitis.10
Despite deﬁned strategies to mitigate PDRP risk,11 the
treatment of PDRP is dependent on patient recognition
of symptoms and presentation to a health facility for
administration of antibiotics. Even with treatment, a
signiﬁcant proportion of episodes of peritonitis result
in hospitalization, catheter loss, or patient death.12
Although it is implicit in international guidelines that
treatment should be timely,13 no study has identiﬁed
the relationship between the timing of administration
of antibiotics and the subsequent chance of recovery,65
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in other infectious and vascular diseases recommend
rapid therapeutic interventions because the outcomes
from intervention are time dependent.14–21 We hy-
pothesized that there was a relationship between the
time of antibiotic administration after presentation
with peritonitis and patient episode outcomes.
MATERIALS AND METHODS
Study Population
All episodes of PDRP in adults treated between August
2012 and July 2014 in Western Australia were pro-
spectively enrolled as part of a clinical audit approved
by the Royal Perth Hospital ethics committee. In 2012
there were 1144 patients receiving dialysis, of whom 320
received PD. At the time of study commencement in
2012, the Western Australia peritonitis rate was 1:21
patient-months, and the Australian average was 1:28
patient-months.1 In Western Australia all patients
receiving outpatient PD are trained and managed by a
publicly funded private provider, Fresenius Medical
Care, and supervised by 3 tertiary hospitals located in
Perth, the capital city. A single statewide PDRP protocol
is used and requires the initial i.p. administration of 2 g
vancomycin and 200 mg gentamicin for all suspected
PDRP episodes pending culture conﬁrmation, with
subsequent treatment duration and adjustments ac-
cording to International Society for Peritoneal Dialysis
(ISPD) guidelines. PD exit-site care protocols include
bacterial wash, dressing, and intranasal mupirocin
administered 5 days per month. Following recognition
of symptoms of possible PDRP, patients are instructed to
contact the 24-hour FreseniusMedical Care service that
advises on management, which may involve treatment
at 1 of 2 Fresenius Medical Care ambulant home care
facilities located in metropolitan Perth, a metropolitan
hospital, or a non-metropolitan health facility according
to time of contact (in working hours vs. out of working
hours) and patient location. Patients may also present
directly to hospital facilities when symptoms are vague
or unrecognized as peritonitis or diagnostic uncertainty
persists after phone contact.
Data Collection
Patient information regarding symptom presentation
and onset at the time of initial presentation was
recorded using a standardized data collection form.
Data were conﬁrmed by access to emergency depart-
ment records, hospital admission notes, laboratory
data, electronic databases, and direct communication
with patients for conﬁrmation of symptom onset and
timing. Data were collected by nursing staff and then
collated and checked by clinicians (KM, PH) for accu-
racy and to resolve any ambiguity. The PDRP episode66data included the following time points: (i) symptom
onset, deﬁned as the time the patient identiﬁed an
abnormality of 1 or more of pain, fever, or cloudy bags;
(ii) initial contact with the medical services, deﬁned as
the time recorded by the institution receiving the pa-
tient; and (iii) time of treatment, deﬁned as the time of
commencement of initial antibiotic administration.
Episodes were excluded from the ﬁnal analysis if data
were missing for 2 or more of these time variables.
Deﬁnitions
After treatment for presumed PDRP, peritonitis was
retrospectively conﬁrmed using the ISPD deﬁnition,13
as the presence of any 2 of the following: (i) abdom-
inal pain or cloudy bag; (ii) white cell count$100 in the
PD efﬂuent with neutrophil count $50% or a neutro-
phil count >50% if the dwell time was <2 hours; (iii) a
positive PD efﬂuent culture. Metropolitan was deﬁned
as <100 km from Perth, non-metropolitan as >100 and
up to 2400 km from Perth. An abnormal exit site was
deﬁned clinically at the time of presentation by the
treating team. Treatment was deﬁned as the adminis-
tration of any antimicrobial therapy, which was then
reconciled as consistent with the Western Australia
PDRP protocol. The treating health facility was coded as
the patient’s initial point of presentation and adminis-
tration of antibiotic therapy, even if subsequently they
re-presented or were admitted to other health facilities.
The following three main time variables were derived:
(i) symptom-to-contact time (SC), deﬁned as the time
from recognition of the ﬁrst patient-described symptom
to the initial time the health provider was contacted; (ii)
contact-to-treatment time (CT), deﬁned as the time be-
tween the ﬁrst health provider contact to the initial
introduction of antimicrobial therapy; and (iii)
symptom-to-treatment time (ST), the sum of SC and CT.
Outcome Measures
The outcome of each PDRP episode was determined at
30 days as (i) resolution of peritonitis (PD-cure), (ii)
Tenckhoff catheter removal, or (iii) death. The com-
posite primary outcome of PD failure (PD-fail) was
deﬁned as either catheter removal or death at 30 days.
Statistical Analysis
Data are summarized using proportions, means, SDs,
medians, and 25th (Q1) and 75th (Q3) quartiles as
appropriate. Logistic regressions were performed to
investigate associations between SC and CT and the
outcome PD-fail. Linearity of the relationship between
outcomes and SC or CT was initially investigated using
fractional polynomials. Where evidence of non-
linearity was detected, the time variable was divided
into quintiles and the proportion in each quintile withKidney International Reports (2016) 1, 65–72
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the proportions changed and then remained altered,
thus identifying a potential cut point in the continuous
variable. If a cut point was observed this was favored
over fractional polynomials for simplicity of interpre-
tation. CT was therefore also investigated as a dichot-
omous variable with a cut point of 4 hours, as this
period is associated with Australian Hospital Emer-
gency Department decision and admission rules and
corresponded to a potential cut point identiﬁed. Two
episodes with particularly large and unlikely values of
CT (>120 hours) were removed from the analysis when
CT was investigated as a continuous variable but were
included in the upper category of the dichotomous
variable.
Associations between outcomes and patient and
episode characteristics were also explored. To deter-
mine whether the relationship between delays and
outcomes was independent of these factors, all vari-
ables signiﬁcant or close to signiﬁcance (P < 0.1) in
univariate analysis were included in a multivariable
model. The ﬁnal model was obtained following a
manual backward stepwise elimination process where
models were examined for indications of inﬂuence
attributable to the removed non-signiﬁcant variable.
Potential modiﬁcation of SC, ST, or CT effects on PD-
fail by gender or institution type was investigated
using an interaction term.38 episodes 
PD-fail
n = 37 paƟents
Hospital
FaciliƟes
130
n = 178
Episodes   
Episodes = 15
116 paƟents
Figure 1. Flow diagram of episodes, presentation, follow-up, and outcom
Kidney International Reports (2016) 1, 65–72Associations between the type of health facility to
which initial presentation was made and patient char-
acteristics were investigated using Wilcoxon rank sum
and c2 tests, while associations with episode charac-
teristics were explored using multinomial logistic
regression.
Due to potential correlations between multiple epi-
sodes for the same patient, robust variance estimates
for all regression models were obtained by applying a
per-person cluster adjustment. Analyses were per-
formed using Stata 13 (StataCorp LP, College Station,
TX), and signiﬁcance was set at P < 0.05.
RESULTS
During the 24-month period there were 178 treated
episodes of presumed PDRP in 122 patients (Figure 1).
A total of 19 episodes and 6 patients were eliminated
from analysis due to incomplete or missing time vari-
ables (n ¼ 11) or outcome data (n ¼ 4) or due to fungal
peritonitis (n ¼ 4), leaving 159 episodes in 116 patients,
of whom 73% had single episodes and the remainder
had 2 episodes (19%) or$3 episodes (8%). Six episodes
were classiﬁed as repeat (same organism, n ¼ 1) or
recurrent (different organism, n ¼ 5).13 Approximately
one-third of patients entered the study receiving
automated PD, and during the study only 3 patients
changed between automated PD and continuous
ambulatory PD. Baseline data of the 116 patients is121 episodes 
resolved
n = 89 paƟents
n = 11 missing Ɵme 
variables
n = 4  missing 
outcome
data
n = 4 fungal 
peritoniƟs9
Ambulant Care 
Facility
48
es. PD, peritoneal dialysis.
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Table 2. Distribution of microorganism by composite outcome
Organism
Total episodes
n (%)
PD-cure
n (%)
PD-fail
n (%)
Other Gram positive 58 (36.9) 47 (39.5) 11 (28.9)
Staphylococcus aureus 19 (12.1) 14 (11.8) 5 (13.2)
Gram negative 31 (19.7) 22 (18.5) 9 (23.7)
Culture negative 47 (29.9) 35 (29.4) 12 (31.6)
Mixed organism 2 (1.3) 1 (0.8) 1 (2.6)
Culture results were available for 157 of 159 episodes.
CLINICAL RESEARCH K Muthucumarana et al.: Timing of Antibiotics in PD Peritonitisshown in Table 1. A cloudy bag was the most
commonly identiﬁed presenting symptom (91%), while
72% had abdominal pain and 63.5% had both. The
ISPD guidelines for diagnosis of peritonitis were met
by 89% of patient episodes treated for PDRP. Causative
organisms by the primary outcome are shown in
Table 2. Gram-positive cocci (50%) and culture nega-
tive (30%) were the most common causative groups.
There was no statistical association between the dis-
tribution of bacterial organisms and PD-fail (P ¼ 0.72).
Thirty-eight (23.9%) episodes led to the primary
composite end point of death (n ¼ 10, 6.3%) or PD
catheter removal (n ¼ 28, 17.6%) at 30 days. Deaths
were attributed to cardiovascular events (n¼ 2), biliary
complications (n ¼ 1), sepsis (n ¼ 6), and unknown
(n ¼ 1). Two of the patients who died had tube removal
prior to death. Characteristics of patient episodes are
compared according to the primary end point (PD-fail)
in Table 3, and for each component of the composite
outcome. Compared with patient episodes associated
with resolution of PDRP (PD-cure), there were a higher
number of females with PD-fail but no signiﬁcant as-
sociation between PD-fail and age, time on PD, auto-
mated PD versus continuous ambulatory PD,
presentation in or outside of standard working hours,
diabetes mellitus, abnormal exit site, aboriginality,
geographic location or presentation, or symptoms at
presentation. Patients who died were older and more
likely diabetic and female.
The median SC was 5.0 hours (Q1–Q3: 1.3–13.9) in
all patients, 5.6 hours (2.9–18.8) in the PD-fail group,
and 5.0 hours (1.0–13.8) in the PD-cure group, with no
association between SC and PD-fail. The median CT
was 2.3 hours (1.2–4.0) in all patients, 3.4 hours (1.6–
6.3) in the PD-fail group, and 2.0 hours (1.0–3.6) in the
PD-cure group. The median ST was 9.0 hours (4.7–
25.3) in all patients, 13.6 hours (7–31) in the PD-failTable 1. Demographics and baseline characteristics of the whole
study population
Variable
All patients (n [ 116)
n (%)
Age (yr)a 62.5 (14.8)
Female 45 (38.8)
Caucasian 83 (71.5)
Aboriginal 14 (12.0)
Diabetes mellitus 58 (50.0)
Metropolitan resident 87 (75.0)
Time on peritoneal dialysis (mo)b 13.2 (4.9–29.8)
Prior peritonitisc 24 (20.1)
Automated peritoneal dialysis 37 (33.3)
Exit site abnormald 14 (12.2)
aMean (SD).
bMedian (first to third quartile).
cPrior peritonitis at first presentation from 157 episodes.
dThe findings were coded as exit site normal or abnormal.
68group, and 8.0 hours (4.0–20.8) in the PD-cure
group. Each hour of delay in the initiation of antimi-
crobial therapy was associated with an increased risk
of catheter loss and death by 5.5% (OR: 1.055; 95% CI:
1.005–1.109; P ¼ 0.032). In the PD-fail group, 42.1%
of episodes compared with 22.7% in the PD-cure
group received treatment $4 hours after initial con-
tact. A CT of $4 hours increased the risk of PD-fail or
death 2.5-fold (OR: 2.47; 95% CI: 1.14–5.4; P ¼ 0.014).
There was no association between presentation within
or outside of working hours and PD-fail. The distri-
bution of treatment times by the composite outcome is
illustrated in Figure 2. The median SC in patients who
presented to hospitals compared with ambulant facil-
ities was 4.6 and 7.8 hours, respectively (P ¼ 0.48),
and the CT was 2.8 and 1.7 hours, respectively
(P ¼ 0.036). The median CT in patients presenting to
hospitals compared with ambulant facilities according
to the composite outcome was 2.5 and 1.5 hours,
respectively, for PD-cure, and 4.0 and 2.5 hours,
respectively, for PD-fail.
In a multivariable logistic regression, a signiﬁcant
interaction between CT (but not SC or ST) and health
facility at presentation was detected (P ¼ 0.013),
indicating that the odds of PD-fail due to treatment
delay was dependent on the initial site of presentation.
No association between CT and PD-fail was detected for
presentation to an ambulant care facility (OR: 0.96;
95% CI: 0.90–1.02; P ¼ 0.22); however, at a hospital-
based facility each additional hour of treatment delay
was found to increase the odds of PD-fail by 6.8% (OR:
1.068; 95% CI: 1.01–1.13; P ¼ 0.015) (Figure 3). Female
sex continued to be independently associated with
a 2.4-fold higher odds of PD-fail compared to males
after adjusting for CT and health facility effects.
Excluding episodes that did not meet the ISPD criteria
for peritonitis did not signiﬁcantly alter the primary
multivariable analysis results (CT in hospitals OR:
1.063; 95% CI: 1.003–1.13; P ¼ 0.04; and female sex
OR: 2.5; 95% CI: 1.09–5.06; P ¼ 0.031). In a separate
analysis examining the association of gender with other
variables including age, diabetes, cloudy bag, efﬂuent
white cell count, previous episodes, abdominal pain,
and CT, there were no signiﬁcant associations found toKidney International Reports (2016) 1, 65–72
Table 3. Demographic and clinical variables according to the composite outcome of PD-fail (death or catheter loss) at 30 days
Variable
PD removed
n [ 28
(17.6%)
Death
n [ 10
(6.3%)
PD-fail
n [ 38
(23.9%)
PD-cure
n [ 121
(76.1%) OR 95% CI P value
Age (yr) (SD) 56.1 (17.6) 74.1 (12.0) 60.8 (18.0) 63.1 (14.0) 0.99 0.96–1.02 0.48
Female 15 (53.6) 7 (70.0) 22 (57.9) 39 (32.2) 2.89 1.34–6.23 0.007
Aboriginal 4 (14.3) 0 (0) 4 (10.5) 14 (11.6) 0.89 0.27–2.96 0.86
Diabetes mellitus 14 (50.0) 8 (80.0) 22 (57.9) 63 (52.0) 1.26 0.59–2.73 0.55
Metropolitana 20 (71.4) 9 (90.0) 29 (76.3) 91 (75.2) 1.06 0.43–2.62 0.9
Time on PD (mo) 10.8 (4.9–15.1) 18.5 (5.3–42.1) 11.6 (5.3–29.0) 20.7 (8.0–32.7) 0.99 0.96–1.01 0.37
Prior peritonitisb 6 (21.4) 5 (50.0) 11 (28.9) 55 (45.5) 0.49 0.22–1.08 0.07
Cloudy efﬂuent 23 (82.1) 8 (80.0) 31 (81.6) 113 (93.4) 0.31 0.104–0.93 0.04
Abdominal pain 23 (82.1) 6 (60.0) 29 (76.3) 84 (69.4) 1.41 0.61–3.27 0.41
Fever 8 (28.6) 4 (40.0) 12 (31.6) 27 (22.3) 1.60 0.72–3.56 0.24
Exit site abnormalc 3 (10.7) 1 (10.0) 4 (10.5) 15 (12.9) 0.79 0.25–2.48 0.69
CAPDd 16 (64.0) 6 (66.7) 22 (64.7) 78 (65.0) 0.99 0.43–2.28 0.98
APDd 9 (36.0) 3 (33.3) 12 (35.3) 42 (35)
ISPD peritonitis deﬁned 27 (96.4) 8 (80.0) 35 (92.1) 106 (89.0) 1.43 0.38–5.44 0.59
Initial presentation to a
hospital-based facility
20 (71.4) 10 (100.0) 30 (78.9) 83 (68.6) 1.71 0.73–3.99 0.21
1st contact: 8 AM–6 PM 18 (64.3) 7 (70.0) 25 (65.8) 82 (67.8) 0.91 0.43–1.93 0.81
SC (h) 7.2 (3.5–25.3) 4.5 (2.5–6.5) 5.6 (2.9–18.8) 5.0 (1.0–13.8) 1.002 0.99–1.01 0.73
ST (h) 12.4 (7.5–32.5) 16.3 (5–30.3) 13.6 (7–31) 8.0 (4–20.8) 1.003 0.99–1.01 0.48
CT (h) 3.6 (1.4–5.9) 2.8 (2–19.5) 3.4 (1.6–6.4) 2.0 (1.00–3.6) 1.055 1.005–1.11 0.032
CT >4 h 12 (43) 4 (40) 16 (42.1) 27 (22.7) 2.47 1.14–5.38 0.02
OR by logistic regression on composite outcome, data as mean (SD) or median and ﬁrst to third quartile or n (%).
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CI, conﬁdence interval; CT, contact-to-treatment time; ISPD, International Society for Peritoneal
Dialysis; OR, odds ratio; PD, peritoneal dialysis; SC, symptom-to-contact time; ST, symptom-to-treatment time.
aLess than 100 km from Perth city.
bPrior peritonitis episode defined as treated peritonitis >4 weeks before presentation.
cRecorded for 154 episodes as exit site normal or abnormal.
dData missing for 5 episodes; OR for CAPD compared with APD shown.
K Muthucumarana et al.: Timing of Antibiotics in PD Peritonitis CLINICAL RESEARCHpotentially account for the higher female PD-fail
outcome (data not shown).
DISCUSSION
This study demonstrated that in PDRP episodes pre-
senting to hospitals, every hour of antibiotic-treatment
delay from the initial contact with a hospital facility
increases the odds of the composite outcome of catheter
loss and death. The time from symptom onset to pre-
sentation to a health facility for antibiotic treatment,
although numerically greater than that from presenta-
tion to treatment, was not associated with the com-
posite outcome. In contrast with other studies,
diabetes, age, aboriginality, organism type, automated
PD versus continuous ambulatory PD, abnormal exit
site, time on PD, and prior peritonitis episodes were not
associated with the outcome. Although ISPD guidelines
implicitly recognize that antibiotic treatment is a pri-
ority based on expert opinion, there is no evidence to
support a relationship between the timing of adminis-
tration of antibiotics and PD-related outcomes. Many
studies in medicine support antibacterial therapy dur-
ing the “golden hour” or “antibiotics as soon as
possible,” including meningitis,21 Pseudomonas17 and
staphylococcal18 bacteremia, septic shock, and pneu-
monia.15,16,19,20 The principle is also well recognized inKidney International Reports (2016) 1, 65–72acute vascular syndromes such as stroke22 and
myocardial infarction.23 The timely administration of
antimicrobial therapy in hypotensive patients with
sepsis was associated with increased survival to hos-
pital discharge, and there was a linear relationship
between timing of antibiotic administration and sur-
vival.24 Houck et al.16 similarly demonstrated that a
>4-hour delay in administration of antibiotics after an
intensive care unit admission increased mortality in
community-acquired pneumonia. The ﬁnding of a
similar relationship between treatment delay and out-
comes in PD peritonitis in this study is consistent with
established infectious disease evidence and, to our
knowledge, the ﬁrst to document such an association.
The high rate of patient death or catheter loss at 30
days observed in this cohort is consistent with out-
comes reported in Australia1 and other international
studies.25–27 The 3-step process of symptom recogni-
tion, health-provider contact, and administration of
antibiotic allows multiple potential barriers to timely
treatment. The adverse effect of delayed antibiotic
administration detected only in patients treated in
hospitals may, in part, be due to self-selection of the
better patient to an ambulant care facility whereas
sicker patients are more likely to be referred or present
directly to hospitals. Patients attending an ambulant69
Figure 2. Distribution of time variables (box-and-whisker plots) by composite outcome. CT, contact-to-treatment time; SC, symptom-to-contact
time; ST, symptom-to-treatment time.
CLINICAL RESEARCH K Muthucumarana et al.: Timing of Antibiotics in PD Peritonitiscare facility had earlier treatment times than those
presenting to hospitals in both the PD-fail and PD-cure
groups. Ambulant care services in this study only
manage patients receiving dialysis and are more likely
to be familiar with the presenting symptoms and signs
and rapidly assess and deliver care without awaiting
unnecessary tests, additional clinical review, or medical
approval. In contrast, presentation to hospitals withFigure 3. Multivariable model for predictors of the composite outcome PD
ratio.
70differing triage priorities and variable familiarity with
PDRP may impose delays pending additional tests and
medical review, despite the existence of established
treatment protocols. However, no association between
presentation within or outside working hours and
outcome was found. We did not show the timing from
onset of symptoms, or remoteness from a health facil-
ity, to be associated with an adverse outcome. Patient-fail. CI, conﬁdence interval; CT, contact-to-treatment time; OR, odds
Kidney International Reports (2016) 1, 65–72
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or recalling their onset accurately, is suggested by the
wide spread of symptom time prior to hospital contact
and may account for the absence of any association
between symptom duration and outcome.
Females had twice the odds of catheter loss or death.
This is consistent with some27,28 but not other
studies.5,29 We could not identify any additional
gender-speciﬁc differences within our study that might
explain this ﬁnding. It is likely that variability and bias
in patient selection, inclusion of different variables,
and different study populations contribute to the re-
ported differences in outcome by gender.
We included patients who were presumptively
treated for PDRP and used the diagnostic criteria of the
ISPD guidelines for veriﬁcation. The majority met these
deﬁnitions, indicating a high degree of clinically
appropriate treatment. The failure to fully conﬁrm
diagnostic criteria in all cases may have been due to
inadequate sample collection, prior antibiotic exposure,
and laboratory technical aspects. Variability in the
pathogenicity of causative microorganisms is a recog-
nized factor associated with varying risk of technique
failure and mortality. Gram-positive peritonitis has
often shown better resolution rates compared with
other bacterial infection, and non-Pseudomonas Gram-
negative infections have better outcomes over Pseudo-
monas infections.17,27,30,31 The rate of culture-negative
episodes was slightly higher in our study compared
with other reports, although consistent with contem-
porary Australian data.2 We speculate that varying
laboratory collection standards and timing of collection
of samples across a large geographical provider base
might inﬂuence these results. In our study the distri-
bution of bacteria and culture-negative peritonitis was
not different between patients who recovered or failed
treatment, suggesting that the timing of the adminis-
tration of appropriate antibiotics is a better predictor of
outcome than the type of infection. However, small
sample size may have restricted the opportunity to
discern an effect of speciﬁc organisms and response to
treatment. Despite registry data suggesting that
remoteness and aboriginal race4 are associated with
inferior PDRP outcomes, this was not conﬁrmed in our
study, perhaps because of the smaller patient numbers
in our study, or because the timing of administration of
antibiotics is unaccounted for as a confounder in reg-
istry data analysis.
This study has several strengths and limitations. We
provided a “real world” evaluation of treatment of PDRP
in a diverse population managed by multiple health
providers across a vast geographic area. All the patients
were treated according to a standardized local protocol,
and we obtained follow-up data on all included episodesKidney International Reports (2016) 1, 65–72and patients. Data were collected from consecutive ep-
isodes with prospective recruitment and retrospective
data conﬁrmation. We included a small number of epi-
sodes that did not meet the ISPD guidelines for perito-
nitis; however, we show that exclusion of these patients
does not alter the conclusions of this study. In our study,
antibiotic treatment was administered at a wide range of
geographically dispersed health care providers, which
may not be typical of other health care providers or
health networks.
In conclusion, we have demonstrated, for the ﬁrst
time to our knowledge, an independent graded and
signiﬁcant association between contact with a medical
facility with presumed PDRP, and the time of the initial
administration of antimicrobial therapy, and the risk of
technique failure and mortality. This increased risk was
conﬁned to those presenting via hospitals when
compared with ambulant care dialysis facilities, poten-
tially implicating health care system impediments to
timely care. These data suggest the requirement of new
research, exploring strategies to expedite the timely
delivery of antibiotics to improve the current PDRP
outcomes and reduce the risk of death or catheter loss.
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